TRxADE HEALTH INC
For the period ended Dec 31, 2023. Filed Apr 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 22, 2024
SCNX$3.20+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
Years Ended December 31, 2023 and 2022
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues | $8,272,214 | $10,250,168 |
| Cost of sales | 5,673,957 | 4,730,897 |
| Gross Profit | 2,598,257 | 5,519,271 |
| Operating Expenses: | ||
| Loss on inventory investment | - | 875,250 |
| Wage and salary expense | 2,698,178 | 3,581,089 |
| Professional fees | 1,466,567 | 466,735 |
| Accounting and legal expense | 1,534,377 | 829,751 |
| Technology expense | 1,376,908 | 993,185 |
| General and administrative | 2,785,633 | 1,689,230 |
| Total operating expenses | 9,861,663 | 8,435,240 |
| Operating Loss | (7,263,406) | (2,915,969) |
| Nonoperating Income (Expense) | ||
| Change in fair value of warrant liability | (148,420) | 825,544 |
| Interest income | 4,198 | 20,989 |
| Goodwill impairment | (5,129,115) | - |
| Gain on disposal of asset | - | 2,200 |
| Other income | 14,543 | - |
| Interest expense | (1,198,346) | (336,206) |
| Total nonoperating income (expense) | (6,457,140) | 512,527 |
| Net loss from continuing operations | (13,720,546) | (2,403,442) |
| Net loss on discontinued operations | (4,123,028) | (1,506,426) |
| Net Loss | (17,843,574) | (3,909,868) |
| Net loss attributable to TRxADE Health, Inc. | (17,843,574) | (3,472,099) |
| Net loss attributable to non-controlling interests | - | (437,769) |
| Net loss per common share from continuing operations | ||
| Basic | $(17.96) | $(3.48) |
| Diluted | $(5.76) | $(3.47) |
| Net loss per common share from discontinued operations | ||
| Basic | $(5.40) | $(2.67) |
| Diluted | $(1.73) | $(2.66) |
| Net loss attributable to common stockholders | ||
| Basic | $(23.35) | $(6.15) |
| Diluted | $(7.49) | $(6.13) |
| Weighted average common shares outstanding | ||
| Basic | 764,058 | 564,862 |
| Diluted | 2,381,443 | 566,609 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.